Clinical Trials

CNSDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckThoracic

Melanoma, Skin Neoplasms

NCT06047379 2026-03-02

Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis

Phase 1/2 Recruiting

134 enrolled

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Astrocytoma, Brain Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Glioblastoma, Melanoma, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Central Nervous System Neoplasms, Small Cell Lung Carcinoma

NCT03400332 2026-02-24

A Study of BMS-986253 in Combination With Nivolumab or Nivolumab Plus Ipilimumab in Advanced Cancers

281 enrolled 44 charts

Melanoma, Neoplasms

NCT06581406 2026-02-18

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma

Phase 2/3 Recruiting

280 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT04196452 2025-11-20

A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR)

Active not recruiting

10 enrolled

Phase 1/2 Active not recruiting

Melanoma

NCT06784648 2025-11-19

Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma

35 enrolled

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT07091695 2025-11-12

Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab

Completed

100 enrolled

Melanoma

NCT04935229 2025-10-22

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

67 enrolled

DermatologicGastrointestinalGenitourinaryOther solid neoplasmThoracic

Uveal Melanoma

NCT06362369 2025-09-17

A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy

Phase 1/2 Recruiting

126 enrolled

Turcot syndrome, Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Kidney Neoplasms, Liver Neoplasms, Melanoma, Neoplasm Metastasis, Skin Neoplasms, Colorectal Neoplasms

NCT06624644 2025-09-10

A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma

Phase 2/3 Recruiting

135 enrolled

Melanoma

NCT03126110 2025-08-14

Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

145 enrolled 47 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasm Metastasis, Ovarian Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT05116202 2025-07-18

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)

110 enrolled 27 charts

DermatologicHead & NeckThoracic

Melanoma

NCT03645928 2025-06-19

Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

Phase 2 Recruiting

245 enrolled

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02259231 2025-06-04

RTA 408 Capsules in Patients With Melanoma - REVEAL

41 enrolled 15 charts

Melanoma, Neoplasm Metastasis

NCT01844505 2025-05-21

Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)

945 enrolled 19 charts

Melanoma

NCT02388906 2025-04-24

CheckMate 238

906 enrolled 16 charts 1 FDA

Melanoma

NCT05909995 2025-02-18

Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors

DermatologicGastrointestinalGenitourinary

8 enrolled

Turcot syndrome, Carcinoma, Renal Cell, Carcinoma, Hepatocellular, Melanoma, Colorectal Neoplasms

NCT04382664 2025-01-14

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

156 enrolled 11 charts

Melanoma

NCT04121676 2025-01-13

Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced Cancer

91 enrolled

Melanoma

NCT02275416 2024-12-16

Safety of UV1 Vaccination in Combination With Ipilimumab in Patients With Unresectable or Metastatic Malignant Melanoma

12 enrolled

Melanoma

NCT03153085 2024-12-09

A Study of Combination with TBI-1401(HF10) and Ipilimumab in Japanese Patients with Unresectable or Metastatic Melanoma

28 enrolled

Melanoma

NCT03978611 2024-07-24

A Study to Assess Safety of Relatlimab With Ipilimumab in Participants With Advanced Melanoma Who Progressed on Anti-Programmed Cell Death Protein 1 (Anti-PD-1) Treatment

11 enrolled

Melanoma

NCT03752398 2024-07-05

DUET-3

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

198 enrolled

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Urinary Bladder Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms, Melanoma, Pancreatic Neoplasms, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Histiocytoma, Malignant Fibrous, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT03711188 2024-04-29

A Study of IMM-101 in Combination With Checkpoint Inhibitor Therapy in Advanced Melanoma

16 enrolled 14 charts

Melanoma

NCT01621490 2024-04-23

PD-1

170 enrolled 34 charts

Melanoma

NCT02723006 2024-03-05

Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma

22 enrolled 14 charts

Melanoma

NCT01856023 2023-12-05

PROCLIVITY02

Phase 4 Terminated

29 enrolled 9 charts

Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT03408587 2023-05-06

CLEVER

11 enrolled

Diabetes Mellitus, Insulin-Dependent, 12, Uveal Melanoma, Coxsackievirus Infections, Virus Diseases

NCT02054520 2023-04-18

Immunotherapy Study for Patients With Stage IV Melanoma

Phase 2 Terminated

47 enrolled 16 charts

Melanoma

NCT04311710 2023-02-24

CheckMate 76U

DermatologicGastrointestinalGenitourinaryThoracic

21 enrolled

Urinary Bladder Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasms, Skin Neoplasms

NCT02307149 2023-01-17

MITCI

50 enrolled

Melanoma

NCT03445533 2022-11-08

A Study of Tilsotolimod in Combo With Ipilimumab vs Ipilimumab Alone in Subjects With Anti-PD-1 Refractory Melanoma

Phase 3 Terminated

481 enrolled 22 charts

Diabetes Mellitus, Insulin-Dependent, 12, Melanoma, Neoplasm Metastasis, Skin Neoplasms

NCT03241173 2022-09-27

A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

52 enrolled 25 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Ovarian Neoplasms, Stomach Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT02089685 2022-09-13

MK-3475-029

DermatologicGenitourinary

295 enrolled 25 charts

Carcinoma, Renal Cell, Melanoma

NCT02644967 2022-08-03

ILLUMINATE-204

53 enrolled 21 charts

Melanoma

NCT02714218 2022-06-24

A Study of Two Different Dose Combinations of Nivolumab in Combination With Ipilimumab in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma

387 enrolled 28 charts

Melanoma

NCT00084656 2022-04-14

Monoclonal Antibody Therapy and Vaccine Therapy in Treating Patients With Resected Stage III or Stage IV Melanoma

77 enrolled 13 charts

Uveal Melanoma, Melanoma

NCT02854488 2022-03-31

Yervoy Pregnancy Surveillance Study

Withdrawn

Melanoma

NCT01927419 2022-03-18

CheckMate 069

142 enrolled 16 charts

DermatologicHead & NeckThoracic

Melanoma

NCT03347123 2022-02-28

A Study of Epacadostat and Nivolumab in Combination With Immune Therapies in Participants With Advanced or Metastatic Malignancies (ECHO-208)

Phase 1/2 Terminated

11 enrolled 12 charts

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02381314 2022-02-08

Safety Study of Enoblituzumab (MGA271) in Combination With Ipilimumab in Refractory Cancer

24 enrolled

DermatologicThoracic

Carcinoma, Non-Small-Cell Lung, Melanoma

NCT02320058 2021-10-05

CheckMate204

119 enrolled 23 charts

Melanoma

NCT03068455 2021-09-20

CheckMate 915

1,844 enrolled 14 charts

Melanoma

NCT01783938 2021-08-13

Study of Nivolumab Given Sequentially With Ipilimumab in Subjects With Advanced or Metastatic Melanoma (CheckMate 064)

138 enrolled 12 charts

Melanoma

NCT02599402 2021-06-15

CheckMate 401

533 enrolled 19 charts

Melanoma

NCT04060407 2021-06-01

CINDI

Phase 1/2 Withdrawn

Melanoma

NCT04860076 2021-04-26

Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors

Unknown

400 enrolled

DermatologicThoracic

Lung Neoplasms, Melanoma

NCT01024231 2021-03-22

Dose-escalation Study of Combination BMS-936558 (MDX-1106) and Ipilimumab in Subjects With Unresectable Stage III or Stage IV Malignant Melanoma

127 enrolled 28 charts

Melanoma

NCT04495010 2021-03-19

CheckMate 7UA

Phase 2 Withdrawn